Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04396626 · ClinicalTrials.gov registry record
HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes
A clinical trial, sponsored by Pfizer.
- Terminated
- Registry status
- 975
- Enrollment target
NCT04396626: Clinical Trial study, sponsored by Pfizer.
NCT04396626 is a clinical trial that was terminated before completion, run by Pfizer. The registered enrollment target is 975 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04396626 was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- 975 participants
- Enrollment target
Study Summary
This is a retrospective, observational study that will document the treatment patterns and clinical outcomes of patients diagnosed with HR+/HER2- A/MBC who received CDK4/6i combination therapy with aromatase inhibitors (AI) as the initial endocrine-based therapy in the A/MBC setting.
Primary Outcome
Treatment regimen was defined as one or more anti-cancer agents given in combination, over a period of time.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 975 participants |
| Start Date | 2019-11-18 |
| Est. Completion | 2020-05-31 |
Why NCT04396626 stopped before completion
NCT04396626 is an observational study that tracks outcomes without assigning an intervention. The registered 975 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04396626 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04396626 about?
NCT04396626 is a clinical study titled "HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes". This is a retrospective, observational study that will document the treatment patterns and clinical outcomes of patients diagnosed with HR+/HER2- A/MBC who received CDK4/6i combination therapy with aromatase inhibitors (AI) as the initial endocrine-based therapy in the A/MBC setting.
What is the current status of trial NCT04396626?
This trial is currently terminated. The enrollment target is 975 participants. The study started on 2019-11-18. Estimated completion is 2020-05-31.
Who is sponsoring clinical trial NCT04396626?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- NCT06820736 · 975 participants · NA
A Prospective, Randomized Comparison Of Drainage Techniques After One- Or Two-Level Open Posterior Lumbar Decompression Or Decompression And Fusion
- NCT07216482 · 975 participants · Phase 3
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI